Abstract: The invention provides chroman compounds having formula 1 wherein R1 is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R1 has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R4 is H, Hal, CF3, OH or (1C-2C)alkyloxy; R2, R3, and R5are independently H, Hal, CF3, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof for the manufacture of a medicine for estrogen-receptor related treatments.
Type:
Grant
Filed:
January 10, 2006
Date of Patent:
May 12, 2009
Assignee:
N.V. Organon
Inventors:
Gerrit Herman Veeneman, Neeltje Miranda Teerhuis
Abstract: Disclosed is a novel class of steroid compounds based on estradiol, and carrying an 11?-substitution. Said substitution is a hydrocarbon group which may be linear or branched, provided that it comprises, as the longest chain on carbon atom no. 11 of the steroid skeleton, one single linear chain having a length of from 5 to 9 carbon atoms, wherein said chain may be saturated or unsaturated. The resulting compounds have a desirable mixed agonist/antagonist profile for estrogen receptor ? and estrogen receptor ?.
Type:
Grant
Filed:
November 18, 1999
Date of Patent:
May 5, 2009
Assignee:
N.V. Organon
Inventors:
Hubert Jan Jozef Loozen, Wilhelmus Gerardus Eduardus Joseph Schoonen
Abstract: Embodiments of the present invention generally relate to novel fed-batch fermentations wherein processes of DO-stat and pH-stat are combined for nutrient feeding control.
Type:
Grant
Filed:
May 6, 2005
Date of Patent:
April 21, 2009
Assignee:
N.V. Organon
Inventors:
WengLong Roy Lin, Firoz Rustom Mistry, Arun Narayanaswamy Tholudur, Edward Todd Sorensen, Wan-Seop Kim, Dana Perrin
Abstract: Disclosed herein are methods for treating energy metabolism disorders by administering a composition containing a therapeutically effective amount of a fatty acid amide hydrolase inhibitor. The composition can also be administered to reduce body fat, body weight, or caloric intake.
Type:
Application
Filed:
October 2, 2007
Publication date:
April 16, 2009
Applicant:
N.V. Organon
Inventors:
Jeff A. Parrott, Timothy R. Compton, Olivier Dasse, David Putman
Abstract: The invention relates to an isolated polynucleotide sequence comprising a nucleic acid sequence encoding the amino acid sequence of KshA protein or of KshB protein, encoded by nucleotides 499-1695 of SEQ ID NO:1 or by nucleotides 387-1427 of SEQ ID NO:2, respectively, and functional homologues thereof. The polynucleotides of the invention can be used to construct genetically modified microorganisms blocked in 3-ketosteroid 9?-hydroxylase activity, which are useful in the microbial degradation of steroids to accumulate certain steroid products.
Type:
Grant
Filed:
January 18, 2007
Date of Patent:
April 7, 2009
Assignee:
N.V. Organon
Inventors:
Robert Van Der Geize, Peter Van Der Meijden, Gerda Hessels, Lubbert Dijkhuizen
Abstract: The present invention relates to spiro[2H-1-benzopyran-2,4?-piperidine] derivatives having general formula (I), or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these spiro[2H-1-benzopyran-2,4?-piperidine] derivatives in therapy, more specifically for the treatment of CNS disorders.
Type:
Grant
Filed:
August 8, 2003
Date of Patent:
March 24, 2009
Assignee:
N.V. Organon
Inventors:
Samuel George Gibson, David John Miller
Abstract: The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or SO2; R1, R2, R3 and R4 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, halogen, nitro, cyano, NR8R9, NR8COR10, and CONR8R9, R5, R6 and R7 are independently H or (C1-4)alkyl; R8 and R9 are independently H or (C1-4)alkyl; or R8 and R9 form together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR11; R10 is (C1-4)alkyl; R11 is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
October 25, 2007
Date of Patent:
March 17, 2009
Assignee:
N.V. Organon
Inventors:
Simon James Anthony Grove, Mingqiang Zhang, Mohammad Shahid
Abstract: A nucleotide acid sequence is provided encoding a peptidylargine deiminase 6. The gene is found to be expressed in gonads only and may be used as target for male and female contraception. Its encoded protein can be used to screen for small molecular weight modulators of the enzyme activity.
Type:
Grant
Filed:
April 25, 2003
Date of Patent:
March 10, 2009
Assignee:
N.V. Organon
Inventors:
Jan Albert Gossen, Paul Van den Boogaart
Abstract: The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
February 14, 2006
Publication date:
March 5, 2009
Applicant:
N.V. ORGANON
Inventors:
Ralf Plate, Guido Jenny Rudolf Zaman, Pedro Harold Han Hermkens, Christiaan Gerardus Johannes Maria Jans, Rogier Christian Buijsman, Adrianus Petrus Antonius De Man, Paolo Giovanni Martino Conti, Scott James Lusher, Willem Hendrik Abraham Dokter
Abstract: Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for the preparation of the compound of Formula (I), characterization of polymorphs of the FAAH inhibitor, and their uses therof.
Abstract: The invention relates to a pharmaceutical dosage form comprising an analgesic combination for simultaneous or sequential use which comprises a peripherally restricted cannabinoid CB1 receptor agonist having a brain Cmax to plasma Cmax ratio of less than 0.1 and an opioid receptor agonist, as well as to a method for treating pain using said pharmaceutical dosage form.
Type:
Application
Filed:
July 6, 2006
Publication date:
January 29, 2009
Applicant:
N.V. Organon
Inventors:
Julia Adam-Worrall, David Robert Hill, Jean Cottney
Abstract: The invention relates to 2-(benzimidazol-1-yl)-acetamide bisaryl derivative having the general Formula I wherein n is 0 or 1; Ar1 represents a diradical derived from a 5- or-6-membered aromatic ring, optionally comprising 1-3 heteroatoms selected from N, O and S, said ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy, halogen, CF3 or cyano; Ar2 represents a 6-membered aryl ring, optionally comprising 1-3 nitrogen atoms, said ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl (optionally substituted with 1 or more halogens), (C1-4)alkyloxy (optionally substituted with 1 or more halogens), di(C1-4)alkylamino, halogen, CF3 or cyano; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same and to the use of said 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives in the treatment of TRPV1 mediated disorders.
Abstract: The invention provides a process for the preparation of 2-substituted-derivatives of estrone and estradiol. The invention also provides several novel compounds, which can be intermediates in the process, and processes to prepare these novel compounds. The invention also provides 2-alkoxy-estrone, 2-alkoxy-estradiol or mixtures thereof essentially free from other estrogenic intermediates.
Type:
Application
Filed:
August 1, 2005
Publication date:
January 8, 2009
Applicant:
N.V. Organon
Inventors:
Johannaes Stoelwinder, Nicolaas Elisabeth Moers
Abstract: The invention pertains to a kit for assembling a disposable applicator for inserting an implant, in particular a rod-like implant containing an active substance, under the skin of a human or animal, the kit comprising a first component, in turn comprising a main housing part providing a handle for grasping and maneuvering the applicator, a cannula, and a cannula holder mounted in the main housing part, the main housing part having an opening which allows introduction of an implant into the proximal end of the cannula or the cannula holder, and, a second component for closing said opening, in turn comprising a second housing part and a rod attached to or forming an integral whole with the second housing part and mountable inside the cannula or the cannula holder.
Type:
Application
Filed:
July 17, 2008
Publication date:
January 8, 2009
Applicant:
N.V. ORGANON
Inventors:
Dennis Cornelis Franciscus BEELEN, Martin VAN HARMELEN, Robertus Theodoor Maria Moormann, Maurice Petrus Wilhelmus Tak
Abstract: The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide derivatives and to their use in therapy, particularly for the treatment of obesity or nicotine dependence.
Type:
Application
Filed:
March 17, 2006
Publication date:
November 13, 2008
Applicant:
N.V. Organon
Inventors:
Phillip Martin Cowley, Samuel George Gibson, Grant Wishart
Abstract: The present invention relates to 4-phenyl-5-oxo-1,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R1 is (1-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R2, R3 are independently halogen, (1-4C)allyl, (2-4C)alkenyl, (2-4C)-alkynyl, (1-4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; R4 is phenyl or (2-5C)-heteroaryl, both substituted with R7 and optionally substituted on the (hetero)aromatic ring with one or more substituents selected from hydroxy, amino, halogen, nitro, trifluoromethyl, cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylthio and (di)(1-4C)-alkylamino.
Type:
Application
Filed:
May 2, 2006
Publication date:
November 6, 2008
Applicant:
N.V. Organon
Inventors:
Pedro Manuel Grima Poveda, Willem Frederik Johan Karstens, Cornelis Marius Timmers
Abstract: The present invention relates to (pyrido/thieno)-[f]-oxazepine-5-one derivatives having the general Formula I wherein R1, R2 and R3 are independently H or (C1-4)alkyl; Ar represents a fused thiophene or pyridine ring optionally substituted with one or more substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, CF3, halogen, nitro, cyano, NR4R5, NR4COR6, and CONR4R5; R4 and R5 are independently H or (C1-4-)alkyl; or R4 and R5 form together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR6; R6 is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
February 1, 2008
Publication date:
October 23, 2008
Applicant:
N.V. Organon
Inventors:
Simon James Anthony Grove, Julia Adam-Worall, Mingqiang Zhang, Robert Gilfillan
Abstract: The invention provides for a combination comprising an amount of an SSRI, or a pharmaceutically acceptable salt or solvate thereof, and an amount of a GR antagonist, or a pharmaceutically acceptable salt or solvate thereof, optionally in association with one or more pharmaceutically acceptable carriers for use as therapy for depression and related disorders.
Type:
Application
Filed:
November 16, 2005
Publication date:
October 16, 2008
Applicant:
N.V. Organon
Inventors:
Colin D. Ingram, Morag A. Grassie, Nicol Ferrier, Sasha E. Gartside, Allan E. Young
Abstract: The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
Type:
Application
Filed:
June 29, 2007
Publication date:
October 16, 2008
Applicant:
N.V. Organon
Inventors:
Kevin James Gillen, Craig Jamieson, John Kinnaird Ferguson MacLean, Elizabeth Margaret Moir, Zoran Rankovic